[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100427749":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":41,"collaborators":45,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Capital Medical University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Alzheimer's disease",null,"Criteria for AD according to the 2011 NIA-AA",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-AD dementia","Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.",{"label":16,"type":10,"description":17,"interventionNames":10},"Cognitively normal controls","Individuals with normal cognitive function",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Jianping Jia, Doctor","CONTACT","8610-83199449","jiajp@vip.126.com",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Xuanwu Hospital of Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100053","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jianping Jia","Chief Director",[46,49,51,53,55,57,60,62,64,66],{"name":47,"class":48},"Shandong Provincial Hospital","OTHER_GOV",{"name":50,"class":6},"Xiangya Hospital of Central South University",{"name":52,"class":6},"Zhejiang Provincial People's Hospital",{"name":54,"class":6},"Beijing Geriatric Hospital",{"name":56,"class":6},"Kaifeng Central Hospital",{"name":58,"class":59},"The First Affiliated Hospital of Chongqing Medical Universty","UNKNOWN",{"name":61,"class":6},"Huashan Hospital",{"name":63,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":65,"class":6},"West China Hospital",{"name":67,"class":6},"Henan Provincial People's Hospital","100427749","detection-of-alzheimers-disease-ad-related-seeds-for-ad-diagnosis-100427749",false,"NCT04850053","Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis","Detection of Alzheimer's Disease (AD)-Related Seeds as Biomarkers for Accurate Diagnosis of AD（AD-seeds-detector）","Inclusion Criteria:\n\n* Aged 55-75. Written informed consent obtained from participant or legal guardian prior to any study-related procedures. The diagnosis of AD is made using the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. As for non-AD dementia, the McKeith criteria are used for DLB,the revised diagnostic criteria proposed by the International behavioral variant (bvFTD) Criteria Consortium for bvFTD,the Gorno-Tempini criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic criteria for CJD, etc. In addition, normal cognition is supported by MMSE, CDR and other cognitive function scales.\n\nExclusion Criteria:\n\n* Other medical or psychiatric illness. No one can serve as an informant. Refused to complete a cognitive test and provide biospecimen.",true,"ALL","55 Years","75 Years",{"count":80,"type":81},1500,"ESTIMATED","OBSERVATIONAL","The study will investigate the biomarkers of Aβ and Tau seeds in plasma detected by Alzheimer's disease (AD) related seeds quantitative detector (AD-seeds-detector), and their sensitivity and specificity in diagnosing AD, compared with those from age-matched cognitively normal controls, and those with other types of dementia.\n\nTo perform a high throughput analysis of the amount of Aβ and Tau seeds, the investigators have developed an AD-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.",[85],"Alzheimer's Disease",[9],"2026-03-19",{"date":89,"type":90},"2026-03-23","ACTUAL",{"date":92,"type":90},"2020-08-26",{"date":94,"type":81},"2026-12-31",{"name":5,"class":6},1]